Clinical trial · Interventional
TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
Transcatheter Hepatic Artery Chemoembolization Combined With Immune Checkpoint Inhibitors for Liver Tumors
NCT06487663CI-TRIAL-00078572TIKETrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate the efficacy and safety of TACE combined with immune checkpoint inhibitors to treat unresectable hepatocellular carcinoma.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cholangiocarcinoma Non-resectable | — | UNRESOLVED | — |
| Hepatocellular Carcinoma Non-resectable | — | UNRESOLVED | — |
| Liver Malignant Tumors | — | UNRESOLVED | — |
| Liver Metastases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TACE with ICI | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- TACE combined ICI
- description
- TACE combined ICI
- interventionNames
- Procedure: TACE with ICI
Primary outcomes (2)
- measure
- PFS
- timeFrame
- 3 years
- description
- Progression free survival
- measure
- OS
- timeFrame
- 3 years
- description
- Overall Survival
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed diagnosis of HCC by histology/ cytology or clinical criteria * Sign informed consent * When screening for age, the age should be ≥ 18 years old * Eligible for TACE treatment * ECOG physical condition score is 0 or 1 * No prior systemic therapy for HCC, especially immunotherapy * According to the following mRECIST criteria, at least one measurable intrahepatic lesion is suitable for repeated evaluation Exclusion Criteria: * Have any history of kidney disease or nephrotic syndrome * Evidence of extrahepatic spread (EHS) * Cardiovascular diseases with clinical significance (such as activity), including unstable angina, ≥ grade 2 congestive heart failure, and arrhythmia with poor drug treatment control * Any condition representing a contraindication to TACE as determined by the investigators * Known genetic factors for bleeding or thrombosis; Any previous or current evidence indicating a tendency for bleeding * Individuals who have received immunotherapy (anti PD-1, anti PD-L1, or anti CTLA-4 treatment) * Previously received HAIC (hepatic artery infusion chemotherapy), TACE (hepatic artery chemoembolization), TAE (hepatic artery embolization), or TARE (hepatic artery radiation embolization) * Previously received systemic anti-cancer treatment for HCC ,ICC or liver metastasis.
References
Publications (0)
Data not yet available
No reference posted for this study.